Cargando…

Erratum to: Prevalence and Incidence of Human Papillomavirus (HPV) Infection Before and After Pregnancy: Pooled Analysis of the Control Arms of Efficacy Trials of HPV-16/18 AS04-Adjuvanted Vaccine

Detalles Bibliográficos
Autores principales:	Chen, Jing, Gopala, Kusuma, Puthatta, Akarsh, Struyf, Frank, Rosillon, Dominique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7047228/ https://www.ncbi.nlm.nih.gov/pubmed/32128341 http://dx.doi.org/10.1093/ofid/ofaa036

Ejemplares similares

Prevalence and Incidence of Human Papillomavirus (HPV) Infection Before and After Pregnancy: Pooled Analysis of the Control Arms of Efficacy Trials of HPV-16/18 AS04-Adjuvanted Vaccine
por: Chen, Jing, et al.
Publicado: (2019)

Erratum to: Options in human papillomavirus (HPV) detection for cervical cancer screening: comparison between full genotyping and a rapid qualitative HPV-DNA assay in Ghana
por: Obiri-Yeboah, Dorcas, et al.
Publicado: (2017)

Meta‐analysis of the risk of autoimmune thyroiditis, Guillain‐Barré syndrome, and inflammatory bowel disease following vaccination with AS04‐adjuvanted human papillomavirus 16/18 vaccine
por: Rosillon, Dominique, et al.
Publicado: (2020)

Effectiveness of the AS04‐adjuvanted HPV‐16/18 vaccine in reducing oropharyngeal HPV infections in young females—Results from a community‐randomized trial
por: Lehtinen, Matti, et al.
Publicado: (2019)

Efficacy of the HPV-16/18 AS04-Adjuvanted Vaccine Against Low-Risk HPV Types (PATRICIA Randomized Trial): An Unexpected Observation
por: Szarewski, Anne, et al.
Publicado: (2013)

Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada
por: Kohli, Michele, et al.
Publicado: (2012)

Six‐year multi‐centre, observational, post‐marketing surveillance of the safety of the HPV‐16/18 AS04‐adjuvanted vaccine in women aged 10–25 years in Korea
por: Kim, Chul‐Jung, et al.
Publicado: (2017)

Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12–15 years: Interim analysis of a large community-randomized controlled trial
por: Lehtinen, Matti, et al.
Publicado: (2016)

Efficacy of the AS04-adjuvanted HPV-16/18 vaccine in young Chinese women with oncogenic HPV infection at baseline: post-hoc analysis of a randomized controlled trial
por: Hu, Shangying, et al.
Publicado: (2020)

Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial
por: Einstein, Mark H, et al.
Publicado: (2014)

Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme
por: Angelo, Maria-Genalin, et al.
Publicado: (2014)

Ten‐year immune persistence and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in females vaccinated at 15–55 years of age
por: Schwarz, Tino F., et al.
Publicado: (2017)

Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18–45 years: Follow-up through Month 48 in a Phase III randomized study
por: Einstein, Mark H, et al.
Publicado: (2014)

Immune Response to Human Papillomavirus One Year after Prophylactic Vaccination with AS04-Adjuvanted HPV-16/18 Vaccine: HPV-Specific IgG and IgA Antibodies in the Circulation and the Cervix
por: Costa, Ana Paula Ferreira, et al.
Publicado: (2018)

Safety of the AS04-adjuvanted human papillomavirus (HPV)-16/18 vaccine in adolescents aged 12–15 years: end-of-study results from a community-randomized study up to 6.5 years
por: Bi, Dan, et al.
Publicado: (2019)

Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine
por: Folschweiller, Nicolas, et al.
Publicado: (2019)

Vaccination with a Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Cervical Cancer Vaccine in Korean Girls Aged 10-14 Years
por: Kim, Young-Jae, et al.
Publicado: (2010)

Evolution and Taxonomic Classification of Human Papillomavirus 16 (HPV16)-Related Variant Genomes: HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67
por: Chen, Zigui, et al.
Publicado: (2011)

Human Papillomavirus (HPV) Vaccine Effectiveness and Potential Herd Immunity for Reducing Oncogenic Oropharyngeal HPV-16 Prevalence in the United Kingdom: A Cross-sectional Study
por: Mehanna, Hisham, et al.
Publicado: (2019)

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9–14 years: Results to month 12 from a randomized trial
por: Leung, Ting Fan, et al.
Publicado: (2015)

Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women: Open follow-up of a randomized clinical trial up to 4 years post-vaccination
por: Konno, Ryo, et al.
Publicado: (2014)

Immunogenicity and safety of the AS04-HPV-16/18 and HPV-6/11/16/18 human papillomavirus vaccines in asymptomatic young women living with HIV aged 15–25 years: A phase IV randomized comparative study
por: Folschweiller, Nicolas, et al.
Publicado: (2020)

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years: Results from 2 randomized controlled trials
por: Zhu, Fengcai, et al.
Publicado: (2014)

The levels of anti-HPV16/18 and anti-HPV31/33/35/45/52/58 antibodies among AS04-adjuvanted HPV16/18 vaccinated and non-vaccinated Ugandan girls aged 10–16 years
por: Nakalembe, Miriam, et al.
Publicado: (2014)

Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom
por: Willame, Corinne, et al.
Publicado: (2016)

Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination
por: Östensson, Ellinor, et al.
Publicado: (2015)

Erratum to "Are we armed with the right data? Pooled individual data review of biomarkers in people with severe upper limb impairment after stroke”
por: Hayward, Kathryn S., et al.
Publicado: (2017)

Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18–25 years: Results from a randomized controlled trial
por: Zhu, Feng-Cai, et al.
Publicado: (2014)

Human papillomavirus (HPV) vaccination for the prevention of HPV 16/18 induced cervical cancer and its precursors
por: Damm, Oliver, et al.
Publicado: (2009)

Erratum for Peng et al., “Development of a Spontaneous HPV16 E6/E7-Expressing Head and Neck Squamous Cell Carcinoma in HLA-A2 Transgenic Mice”
por: Peng, Shiwen, et al.
Publicado: (2022)

Primary Screening for Cervical Cancer Based on High-Risk Human Papillomavirus (HPV) Detection and HPV 16 and HPV 18 Genotyping, in Comparison to Cytology
por: Agorastos, Theodoros, et al.
Publicado: (2015)

Erratum: A Three-Pool Model Dissecting Readily Releasable Pool Replenishment at the Calyx of Held
por: Guo, Jun, et al.
Publicado: (2016)

Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study
por: Romanowski, Barbara, et al.
Publicado: (2015)

Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study
por: Rachel Skinner, S., et al.
Publicado: (2016)

Awareness and knowledge of Human Papillomavirus (HPV), HPV‐related cancers, and HPV vaccines in an uninsured adult clinic population
por: Radecki Breitkopf, Carmen, et al.
Publicado: (2016)

Knowledge and Awareness of Cervical Cancer, Human Papillomavirus (HPV), and HPV Vaccine Among HPV-Infected Chinese Women
por: Baloch, Zulqarnain, et al.
Publicado: (2017)

Human papillomavirus (HPV) 16 infection is not detected in rectal carcinoma
por: Martins, Sandra F., et al.
Publicado: (2020)

Characterization of Novel Cutaneous Human Papillomavirus Genotypes HPV-150 and HPV-151
por: Kovanda, Anja, et al.
Publicado: (2011)

A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years
por: Schwarz, Tino F., et al.
Publicado: (2019)

HPV-Type Distribution and Reproducibility of Histological Diagnosis in Cervical Neoplasia in Poland
por: Nowakowski, Andrzej, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_i68gj1qc9sslo352r6kn2n3iha